Pegcetacoplan: a novel treatment option for patients with paroxysmal nocturnal hemoglobinuria
Dr Louis Terriou, CHRU de Lille
PP-17436 – January 2023
In this podcast, Dr. Louis Terriou from the CHRU de Lille will talk us through the key results of the PEGASUS trial. In this study, the complement inhibitor Pegcetacoplan, which specifically targets C3, was compared to eculizumab in adult PNH patients with suboptimal hemoglobin levels despite eculizumab therapy. Apart from addressing these trial results, Dr. Terriou also shares his personal experience with this novel treatment option.
This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with SOBI BV.
The SmPC of Pegcetacoplan can be consulted via the following links: SKP: ASPAVELI, INN-pegcetacoplan (europa.eu); RCP: ASPAVELI, INN-pegcetacoplan (europa.eu)
PP-17700 – January 2023
SUBSCRIBE TO BJH HEMATALKS SERIES